Cargando…

Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy

PURPOSE: To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD). METHODS: This prospective study included 48 treatment-naïve neovascular AMD eyes of 48 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Shinichi, Takahashi, Hidenori, Tan, Xue, Inoue, Yuji, Nomura, Yoko, Arai, Yusuke, Fujino, Yujiro, Kawashima, Hidetoshi, Yanagi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890644/
https://www.ncbi.nlm.nih.gov/pubmed/28765149
http://dx.doi.org/10.1136/bjophthalmol-2017-310284
_version_ 1783312903253786624
author Sakamoto, Shinichi
Takahashi, Hidenori
Tan, Xue
Inoue, Yuji
Nomura, Yoko
Arai, Yusuke
Fujino, Yujiro
Kawashima, Hidetoshi
Yanagi, Yasuo
author_facet Sakamoto, Shinichi
Takahashi, Hidenori
Tan, Xue
Inoue, Yuji
Nomura, Yoko
Arai, Yusuke
Fujino, Yujiro
Kawashima, Hidetoshi
Yanagi, Yasuo
author_sort Sakamoto, Shinichi
collection PubMed
description PURPOSE: To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD). METHODS: This prospective study included 48 treatment-naïve neovascular AMD eyes of 48 patients who received three consecutive monthly injections of ranibizumab at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between November 2010 and August 2012. We collected ~0.2 mL aqueous humour before the first and third (2 months later) injections. Controls were 80 eyes with cataracts without retinal disease. The cytokines C-X-C motif chemokine ligand 1 (CXCL1), interferon-γ-induced protein 10 (IP-10), C-X-C motif chemokine ligand 12 (CXCL12), C-X-C motif chemokine ligand 13 (CXCL13), monocyte chemoattractant protein 1 (MCP-1), CCL11, C-C motif chemokine ligand 11 (CCL11), interleukin-6 (IL-6), interleukin-10 (IL-10) and matrix metalloproteinase 9 (MMP-9) were analysed using multiplex cytokine assays. RESULTS: Mean ages of the patients with AMD and controls were 73 and 75 years, respectively, and 31 (65%) and 37 (46%) subjects were men, respectively. Polypoidal choroidal vasculopathy was found in 27 eyes (56%). Mean concentrations of cytokines in aqueous humour in patients with neovascular AMD before the first and third ranibizumab injections were as follows (in pg/mL): CXCL1, 8.4 and 3.3; IP-10, 110 and 55; CXCL12, 480 and 240; CXCL13, 9.2 and 2.6; MCP-1, 620 and 220; CCL11, 7.1 and 2.8; IL-6, 5.9 and 1.6; IL-10, 0.15 and 0.015 (all p<0.0001), and MMP-9, 0.92 and 1.5 (p=0.0216), respectively. Concentrations of all cytokines decreased significantly after two consecutive ranibizumab injections, except for MMP-9, which increased significantly. CONCLUSIONS: After two monthly consecutive antivascular endothelial growth factor injections, inflammatory cytokine levels in the aqueous humour of the eyes with AMD were strongly suppressed, while MMP-9 levels increased.
format Online
Article
Text
id pubmed-5890644
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-58906442018-04-16 Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy Sakamoto, Shinichi Takahashi, Hidenori Tan, Xue Inoue, Yuji Nomura, Yoko Arai, Yusuke Fujino, Yujiro Kawashima, Hidetoshi Yanagi, Yasuo Br J Ophthalmol Clinical Science PURPOSE: To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD). METHODS: This prospective study included 48 treatment-naïve neovascular AMD eyes of 48 patients who received three consecutive monthly injections of ranibizumab at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between November 2010 and August 2012. We collected ~0.2 mL aqueous humour before the first and third (2 months later) injections. Controls were 80 eyes with cataracts without retinal disease. The cytokines C-X-C motif chemokine ligand 1 (CXCL1), interferon-γ-induced protein 10 (IP-10), C-X-C motif chemokine ligand 12 (CXCL12), C-X-C motif chemokine ligand 13 (CXCL13), monocyte chemoattractant protein 1 (MCP-1), CCL11, C-C motif chemokine ligand 11 (CCL11), interleukin-6 (IL-6), interleukin-10 (IL-10) and matrix metalloproteinase 9 (MMP-9) were analysed using multiplex cytokine assays. RESULTS: Mean ages of the patients with AMD and controls were 73 and 75 years, respectively, and 31 (65%) and 37 (46%) subjects were men, respectively. Polypoidal choroidal vasculopathy was found in 27 eyes (56%). Mean concentrations of cytokines in aqueous humour in patients with neovascular AMD before the first and third ranibizumab injections were as follows (in pg/mL): CXCL1, 8.4 and 3.3; IP-10, 110 and 55; CXCL12, 480 and 240; CXCL13, 9.2 and 2.6; MCP-1, 620 and 220; CCL11, 7.1 and 2.8; IL-6, 5.9 and 1.6; IL-10, 0.15 and 0.015 (all p<0.0001), and MMP-9, 0.92 and 1.5 (p=0.0216), respectively. Concentrations of all cytokines decreased significantly after two consecutive ranibizumab injections, except for MMP-9, which increased significantly. CONCLUSIONS: After two monthly consecutive antivascular endothelial growth factor injections, inflammatory cytokine levels in the aqueous humour of the eyes with AMD were strongly suppressed, while MMP-9 levels increased. BMJ Publishing Group 2018-04 2017-08-01 /pmc/articles/PMC5890644/ /pubmed/28765149 http://dx.doi.org/10.1136/bjophthalmol-2017-310284 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Clinical Science
Sakamoto, Shinichi
Takahashi, Hidenori
Tan, Xue
Inoue, Yuji
Nomura, Yoko
Arai, Yusuke
Fujino, Yujiro
Kawashima, Hidetoshi
Yanagi, Yasuo
Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
title Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
title_full Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
title_fullStr Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
title_full_unstemmed Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
title_short Changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
title_sort changes in multiple cytokine concentrations in the aqueous humour of neovascular age-related macular degeneration after 2 months of ranibizumab therapy
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890644/
https://www.ncbi.nlm.nih.gov/pubmed/28765149
http://dx.doi.org/10.1136/bjophthalmol-2017-310284
work_keys_str_mv AT sakamotoshinichi changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT takahashihidenori changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT tanxue changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT inoueyuji changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT nomurayoko changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT araiyusuke changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT fujinoyujiro changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT kawashimahidetoshi changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy
AT yanagiyasuo changesinmultiplecytokineconcentrationsintheaqueoushumourofneovascularagerelatedmaculardegenerationafter2monthsofranibizumabtherapy